YB002

YB002 is a first-in-class gene therapy designed by YouthBio Therapeutics to transiently express Yamanaka factors (the canonical reprogramming factors, including Oct4, Sox2, Klf4, and c-Myc) in the brain to induce partial cellular reprogramming. This approach aims to reverse age-associated epigenetic alterations, restore youthful gene expression, and improve cellular function while maintaining cell identity. The primary therapeutic target is Alzheimer’s disease, with strong preclinical evidence showing reversal of disease pathology, reduction of epigenetic aging, and improvements in cognitive function in animal models[1][2][3][5][13].